IBIO — iBio, Inc.
$0.73
$-0.03 (-4.00%)
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Market Cap
$51.55M
Forward P/E
-1.3x
52-Week Range
N/A
IBIO Price History
Revenue vs. Net Income
$100K
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
-$23.8M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-37.8%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
7.4x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
578.0%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+891.1%
Dilution · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
